• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

DrChrono, Genomind Partner on EHR-Integrated Personalized Genetic Tests

by Jasmine Pennic 10/01/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

DrChrono, Genomind Partner on EHR-Integrated Personalized Genetic Tests

EHR provider DrChrono Inc. and Genomind, which offers a unique personalized medicine platform that brings innovation to healthcare around the world, today announce a partnership to meet the growing need from both patients and doctors for personalized genetic tests that integrate with electronic health records.

AS part of the partnership, physician practices using DrChrono’s platform can order test kits for Genomind’s Genecept Assay®, which helps guide mental health treatment and has been used by over 120,000 patients. The partnership also includes Genomind’s Mindful DNA Professional®, a genetic test used by clinicians that helps guide lifestyle, diet and/or nutritional supplement decisions to improve the overall health and wellbeing of patients.

The partnership means participating doctors can access Genecept Assay and Mindful DNA Professional patient test results and use Genomind’s real-time gene-drug-environmental interaction tool, Genomind Drug Interaction Guide (G-DIG)®.  G-DIG allows the clinician to utilize the Genecept Assay results and enter a current medication regiment when considering what medications to prescribe to a patient; it quickly checks for gene-drug and drug-drug interactions.

Clinicians and patients will benefit in important ways from the partnership.  When a physician orders test kits through the DrChrono electronic health record platform, it will capture patient demographics and applicable clinical information.  Doctors also will be able to see test results in the application, and final results are stored in the DrChrono information library for the patient, becoming part of the patient’s medical record.

 

“We are proud that DrChrono, after a thorough review, has chosen Genomind for this important initiative.  DrChrono is a leader in helping doctors focus on what matters most—the patient,” said Dr. David Krause, Chief Medical Officer at Genomind.  “We often hear from patients whose health and quality of life have been dramatically improved by Genomind’s genetic test products, whether in the form of medication optimization through information provided by the Genecept Assay or an improvement in wellness provided by Mindful DNA Professional results. We are excited to help even more patients get better, by partnering with DrChrono and the practices it supports.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: drchrono, Genetic Tests

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

Why Brain Health Is Entering Its Infrastructure Era

Brain Health’s Infrastructure Era: Proving Clinical Outcomes with Integrated Neuromotor Tracking

Why Catholic Health Inked a $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

Catholic Health Inks $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

The Real Risk in Healthcare AI Isn’t the Model. It’s the Data. 

Clinical Data Fidelity: The Real Blindspot in Healthcare AI Strategy

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

M&A: Qualtrics Completes $6.75B Acquisition of Press Ganey Forsta

Viz.ai Launches Viz Pulmonary™ Suite: AI-Powered Workflows for COPD, Lung Nodules, and PE

Viz.ai Launches Viz Pulmonary™ Suite: AI-Powered Workflows for COPD, Lung Nodules, and PE

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |